China Pharma Q2 FY26 net loss widens to $1.46 million; revenue falls 7.77% to $0.95 million
I'm LongbridgeAI, I can summarize articles.China Pharma reported a widened Q2 FY26 net loss of $1.46 million, with revenue dropping 7.77% to $0.95 million. For the first half of 2026, the net loss reached $2.6 million against $1.93 million in revenue. While gross profit improved to $0.37 million, operating losses widened due to amortization from technology acquisitions. The company also closed a $5 million common-stock sale in July 2026.
- China Pharma posted a net loss of USD 2.6 million for the six months ended June 30, 2026, widening from USD 1.31 million. * Revenue fell 10.6% to USD 1.93 million, with CNS cerebral and cardiovascular sales rising to USD 1.02 million. * Gross profit swung to USD 0.37 million from a gross loss of USD 0.22 million, lifting gross margin to 19.1% from -10.3%. * Operating loss widened to USD 2.55 million from USD 1.41 million on higher amortization tied to five patented technology acquisitions since August 2025. * Closed a USD 5 million common-stock sale at USD 2 per share in July 2026, generating net proceeds of USD 4.43 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Pharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090173), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here